Learn more →
Back to Expert Scholars
hematologic-oncology / hematologic-oncologyMultiple Myeloma

Suzanne Lentzsch

苏珊娜·伦茨施

MD, PhD

🏢Columbia University Irving Medical Center(哥伦比亚大学欧文医学中心)🌐USA

Director, Multiple Myeloma Program & Professor of Medicine多发性骨髓瘤项目主任暨医学教授

58
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Suzanne Lentzsch leads the Columbia University myeloma program and is an internationally recognized expert in plasma cell biology and BCL-2 inhibition in myeloma. She defined the t(11;14) translocation as a predictive biomarker for venetoclax sensitivity, transforming precision therapy in myeloma.

Share:

🧪Research Fields 研究领域

Multiple Myeloma多发性骨髓瘤
Plasma Cell Biology浆细胞生物学
Venetoclax in t(11;14) Myelomat(11;14)骨髓瘤中的维奈托克
Waldenström Macroglobulinemia华氏巨球蛋白血症

🎓Key Contributions 主要贡献

Venetoclax in t(11;14) Myeloma

Led pivotal translational and clinical studies demonstrating that BCL-2 overexpression driven by t(11;14) translocation sensitizes myeloma cells to venetoclax, enabling precision selection of patients for BCL-2 inhibitor therapy.

Plasma Cell Biology and Myeloma Pathogenesis

Investigated molecular mechanisms governing plasma cell differentiation and survival in the bone marrow microenvironment, identifying novel therapeutic vulnerabilities in myeloma and Waldenström macroglobulinemia.

Novel Combinations with Venetoclax

Designed and led clinical trials examining venetoclax combinations with daratumumab and bortezomib in t(11;14) myeloma, establishing response rates and safety profiles informing current trial design.

Representative Works 代表性著作

[1]

Venetoclax Monotherapy in Relapsed/Refractory t(11;14) Multiple Myeloma

Journal of Clinical Oncology (2021)

Phase II study demonstrating high response rates with venetoclax monotherapy in t(11;14) myeloma, establishing proof of concept for BCL-2 inhibition.

[2]

BCL-2 Dependence and Venetoclax Sensitivity in Multiple Myeloma

Blood (2018)

Mechanistic study identifying t(11;14) translocation and BCL-2 high/BCL-XL low expression as predictors of venetoclax sensitivity.

[3]

Venetoclax, Daratumumab, and Dexamethasone in t(11;14) Myeloma

Blood Cancer Journal (2023)

Phase I/II trial of triple combination showing deep responses and manageable safety in relapsed t(11;14) myeloma.

🏆Awards & Recognition 奖项与荣誉

🏆International Myeloma Society Scientific Achievement Award
🏆Leukemia & Lymphoma Society Scholar Award
🏆Columbia University Herbert Irving Comprehensive Cancer Center Research Excellence Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 苏珊娜·伦茨施 的研究动态

Follow Suzanne Lentzsch's research updates

留下邮箱,当我们发布与 Suzanne Lentzsch(Columbia University Irving Medical Center)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment